Literature DB >> 9195740

Characterization of the subclinical phase of canine ehrlichiosis in experimentally infected beagle dogs.

T Waner1, S Harrus, H Bark, E Bogin, Y Avidar, A Keysary.   

Abstract

Beagle dogs were examined during the subclinical phase of canine ehrlichiosis under controlled conditions. Emphasis was placed on gathering data before artificial inoculation with Ehrlichia canis, and comparing these data with those of the subclinical phase of the disease. In this study all dogs were clinically healthy throughout the 6 month examination period. All subclinically infected dogs had IFA antibody titers to E. canis at a dilution varying from 1:2560 to 1:20480. The most prominent haematological finding was mild thrombocytopenia with a concomitant increase in platelet size, seen in eight of the nine dogs examined. Leukocyte counts were statistically significantly reduced in 78% of the dogs, compared with their preinfection values, with 71% of dogs having significantly reduced absolute neutrophil counts. None of the dogs were either leukopenic nor neutropenic. Six of the nine dogs had increased serum gamma-globulin concentrations. No dogs were overtly anemic, although declines in packed cell volume, haemoglobin concentration and total erythrocyte count were detected in an inconsistent manner among the dogs. It was concluded that, the most reliable parameters for judging possible subclinical ehrlichial infection in beagle dogs was mild thrombocytopenia, together with a persistently high antibody titer to E. canis. Hypergammaglobulinemia would increase the suspicion further. Based on the results presented, routine testing of dogs in E. canis endemic areas is recommended in order to identify and treat dogs in the subclinical phase of the disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9195740     DOI: 10.1016/s0304-4017(96)01130-2

Source DB:  PubMed          Journal:  Vet Parasitol        ISSN: 0304-4017            Impact factor:   2.738


  16 in total

Review 1.  Recent advances in determining the pathogenesis of canine monocytic ehrlichiosis.

Authors:  S Harrus; T Waner; H Bark; F Jongejan; A W Cornelissen
Journal:  J Clin Microbiol       Date:  1999-09       Impact factor: 5.948

2.  Efficacy of a doxycycline treatment regimen initiated during three different phases of experimental ehrlichiosis.

Authors:  Jennifer C McClure; Michelle L Crothers; John J Schaefer; Patrick D Stanley; Glen R Needham; S A Ewing; Roger W Stich
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

3.  Amplification of ehrlichial DNA from dogs 34 months after infection with Ehrlichia canis.

Authors:  S Harrus; T Waner; I Aizenberg; J E Foley; A M Poland; H Bark
Journal:  J Clin Microbiol       Date:  1998-01       Impact factor: 5.948

4.  Use of a recombinant positive control in the diagnostic of canine Ehrlichiosis from 16sRNA gen of Ehrlichia canis in Mexico City.

Authors:  S E Acevedo-Monroy; J M Méndez-Alemán; I Castro-Mendoza; M A Mojica-Sánchez; A Verdugo-Rodríguez
Journal:  Arch Microbiol       Date:  2022-09-12       Impact factor: 2.667

5.  Therapeutic effect of doxycycline in experimental subclinical canine monocytic ehrlichiosis: evaluation of a 6-week course.

Authors:  S Harrus; T Waner; I Aizenberg; H Bark
Journal:  J Clin Microbiol       Date:  1998-07       Impact factor: 5.948

6.  Retrospective clinical and molecular analysis of conditioned laboratory dogs (Canis familiaris) with serologic reactions to Ehrlichia canis, Borrelia burgdorferi, and Rickettsia rickettsii.

Authors:  Diana G Scorpio; Lynn M Wachtman; Richard S Tunin; Nicole C Barat; Justin W Garyu; J Stephen Dumler
Journal:  J Am Assoc Lab Anim Sci       Date:  2008-09       Impact factor: 1.232

7.  Clinical, serological, and molecular evidence of ehrlichiosis and anaplasmosis in dogs in Tunisia.

Authors:  Y M'ghirbi; A Ghorbel; M Amouri; A Nebaoui; S Haddad; A Bouattour
Journal:  Parasitol Res       Date:  2008-11-19       Impact factor: 2.289

Review 8.  Host surveys, ixodid tick biology and transmission scenarios as related to the tick-borne pathogen, Ehrlichia canis.

Authors:  R W Stich; John J Schaefer; William G Bremer; Glen R Needham; Sathaporn Jittapalapong
Journal:  Vet Parasitol       Date:  2008-09-12       Impact factor: 2.738

9.  Tick acquisition of Ehrlichia canis from dogs treated with doxycycline hyclate.

Authors:  John J Schaefer; Glen R Needham; William G Bremer; Yasuko Rikihisa; S A Ewing; R W Stich
Journal:  Antimicrob Agents Chemother       Date:  2007-07-02       Impact factor: 5.191

10.  Pharmacokinetics of an injectable long-acting formulation of doxycycline hyclate in dogs.

Authors:  Lilia Gutiérrez; Zazil-Ha Velasco; Carlos Vázquez; Dinorah Vargas; Héctor Sumano
Journal:  Acta Vet Scand       Date:  2012-06-08       Impact factor: 1.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.